AUBAGIO

• tagApproval56 co-mentions · 14 sources
• drugteriflunomide29 co-mentions · 15 sources
• company$SNYSanofi28 co-mentions · 14 sources
• company$SNYNFSanofi28 co-mentions · 14 sources
• tagSmall Molecule28 co-mentions · 14 sources
• companyGlenmark Pharmaceuticals Ltd3 co-mentions · 1 sources
• tagRecall1 co-mentions · 1 sources

Trials studying AUBAGIO

• phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)active not recruitingn=1,000
• phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)active not recruitingn=1,007
• phase3Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosisrecruitingn=1,600
• —A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosisrecruitingn=800
• phase3Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)active not recruitingn=751
• phase3A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)active not recruitingn=746
• phase3A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.active not recruitingn=2,500
• phase4Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weekscompletedn=82